COMP360

Compass Pathways (NASDAQ:CMPS) has announced delays for two key Phase 3 clinical trials involving its psilocybin program, widely seen as a leader in the psychedelic drug development space. As Endpoint News reported, the unexpected timeline shifts, unveiled in the company's third-quarter earnings...

A groundbreaking study from New York’s Columbia University suggests that psilocybin, the psychoactive compound in magic mushrooms may offer relief to individuals suffering from body dysmorphic disorder (BDD). The research, published in Psychedelics, explored the effects of psilocybin on brain...

Compass Pathways (NASDAQ:CMPS), one of the key players in the psychedelics biotech space, reported its financial results for the fourth quarter of 2023. Numbers: Cash and cash equivalents were $220.2 million by December 31, 2023, up over 50% as compared to the amount held by December 31, 2022 ($...

Psychedelics biotech company Compass Pathways (NASDAQ: CMPS) announced it will conduct two separate Phase 3 clinical trials to study psilocybin-assisted therapy on Treatment-Resistant Depression (TRD), reported Microdose.  Assuming positive results, Compass will...

Psychedelics mental healthcare company Compass Pathways PLC. (NASDAQ: CMPS) has launched a phase 2 clinical study testing the efficacy of psilocybin with psychological support in people with anorexia nervosa. The trial will compare the effects of 25 mg and 1 mg of COMP360 (...

Psilocybin is known as the active compound in so-called “magic mushrooms”, yet most psilocybin used in clinical trials today is synthesized in laboratories without the use of biological material. As psychedelics-assisted therapy gains momentum, investors need to understand the...

Compass Pathways (NASDAQ: CMPS), the first and only psychedelics company to list on a major U.S. stock exchange, released its financial results for the fourth quarter and year-end 2020. The company is currently recruiting patients for a phase IIb clinical trial of COMP360, a proprietary...

Compass Launches Center Of Excellence Compass Pathways (NASDAQ: CMPS) officially launched the Centre of Excellence, in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland. This “clinic model” will study and...

Cybin Raises CA$45 Million and Heads Towards NEO Exchange This week, Toronto-based Cybin Corp. announced the closing of a private offering for CA$45 million ($34.2 million). The raise was completed in connection to Cybin’s previously-announced reverse take-over with Clarmin Explorations (TSXV...